A multinational case series describing successful treatment of persistent SARS-CoV-2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir.

Snell, Luke B., McGreal-Bellone, Aimee, Nye, Clemency, Gage, Sarah, Bakrania, Prijay, Williams, Tom G.S., Aarons, Emma, Botgros, Alina, Douthwaite, Samuel T, Mallon, Patrick, Milligan, Iain, Moore, Catherine, O'Kelly, Brendan, Underwood, Jonathan ORCID: https://orcid.org/0000-0001-6963-2821, de Barra, Eoghan and Nebbia, Gaia 2024. A multinational case series describing successful treatment of persistent SARS-CoV-2 infection caused by Omicron sublineages with prolonged courses of nirmatrelvir/ritonavir. Open Forum Infectious Diseases 11 (1) , ofad612. 10.1093/ofid/ofad612

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (431kB) | Preview

Abstract

The optimum treatment for persistent infection with SARS-CoV-2 is not known. Our case series, across 5 hospitals in 3 countries, describes 11 cases where persistent SARS-CoV-2 infection was successfully treated with prolonged courses (median 10 days, range 10-18) of nirmatrelvir/ritonavir (Paxlovid). Most cases (9/11) had haematological malignancy and ten (10/11) had received CD20 depleting therapy. The median duration of infection was 103 days (IQR 85-138). The majority (10/11) were hospitalised, and seven (7/11) had severe/critical disease. All survived and 9/11 demonstrated viral clearance, almost half (4/9) of whom received nirmatrelvir/ritonavir as monotherapy. This case series suggests prolonged nirmatrelvir/ritonavir has a role in treating persistent infection.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Oxford University Press
ISSN:	2328-8957
Date of First Compliant Deposit:	20 December 2023
Date of Acceptance:	10 November 2023
Last Modified:	19 Feb 2024 14:17
URI:	https://orca.cardiff.ac.uk/id/eprint/165003

Actions (repository staff only)

Edit Item